Form 4: Vir Biotechnology Exec Sells Shares Under 10b5-1 Plan

Marianne De Backer, President and CEO of Vir Biotechnology, Inc., reported a transaction involving the sale of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Marianne De Backer, President and CEO of Vir Biotechnology, Inc., engaged in a transaction on April 6, 2026.
• The transaction involved the sale of 72,559 shares of common stock at a price of $9.156 per share.
• This sale was conducted under a Rule 10b5-1 trading plan, designed to satisfy tax withholding obligations related to the vesting of restricted stock units.
• The sale was automatic and mandatory, not a discretionary trade by Ms. De Backer.
• Following this transaction, Ms. De Backer directly beneficially owns 948,145 shares of common stock.
• Additionally, 53,118 shares are held indirectly in the Ureel-De Backer Family Trust, where Ms. De Backer and her spouse are trustees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported stock sale is a routine transaction under a pre-established plan for tax purposes and does not indicate a change in the executive's confidence in the company.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies and potentially mitigating insider trading concerns.
• The sale was to satisfy tax withholding obligations, a common and expected event upon vesting of restricted stock units.
• Ms. De Backer retains a significant direct beneficial ownership of 948,145 shares and indirect ownership of 53,118 shares, demonstrating continued substantial investment in the company.

Negatives

• A sale of company stock by a top executive, even if under a pre-arranged plan, can sometimes be perceived negatively by the market.
• The sale represents a reduction in the reporting person's direct holdings, although the amount is tied to tax obligations.

Risks

• The filing does not explicitly detail risks associated with the transaction itself, as it is a standard procedure for tax withholding.
• Potential market perception of insider selling, even if pre-planned, could be a risk.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports a past transaction.

Management Comments

• The sale does not represent a discretionary trade by the Reporting Person.
• The sale is under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice in the biotechnology sector to manage personal finances and comply with tax obligations while adhering to insider trading regulations. This filing reflects a standard procedural transaction rather than a strategic shift.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related sale and not indicative of a change in management's strategic outlook. The executive retains significant ownership.
• Employees: This filing relates to executive compensation and tax obligations, with no direct impact on general employee equity or benefits.
• Management: Demonstrates adherence to corporate governance policies regarding insider trading and equity compensation management.

Next Steps

• Continued adherence to the Rule 10b5-1 plan for any future vesting and tax obligations.
• Ongoing monitoring of Marianne De Backer's beneficial ownership and any future transactions.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Restricted Stock Units, Tax Withholding, Marianne De Backer, Beneficial Ownership, Executive Compensation